New drug combo targets Hard-to-Treat cancers
Disease control
Completed
This study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…
Phase: PHASE1, PHASE2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC